Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jul 14, 2021 1:02pm
170 Views
Post# 33542848

RE:What is the bottom before next catalyst?

RE:What is the bottom before next catalyst?Difficult to say where the bottom is given the fact that the stock is not performing rationally and there's a major disconnect between the stock price and the attributable factors that suggest the price should probably be higher than where it is now.

The 52 week low is $3.05, you can possibly use that as a reasonable number, but again the stock seems to be absent of any rationale at the moment.
There is $1.87 per share in cash currently.

At some point, this is going to reverse. You can debate as to when that may be, there's a whole host of catalysts which could potentially turn this around.

Personally, I keep my focus on the end goal, successful completion of phase 3 and FDA approval to follow which would obviously result in a much diferent scenario than where things are now (although I highly doubt it will take that long for the stock to produce a reversal, I think it will happen well before that time, but I maintain that end result as the goal).


CoffeeBeans wrote: Bleeding pennies a day and the next real catalyst is this Fall or likely sometime next year, does anyone want to weigh in on where this will bottom?


<< Previous
Bullboard Posts
Next >>